Current Cetirizine Supply Status for Providers

As of March 2026, Cetirizine (Zyrtec) is not listed on the FDA's Drug Shortage Database. No formal nationwide shortage exists for oral Cetirizine formulations. However, clinicians should be aware that patients are reporting intermittent difficulty locating Cetirizine at retail pharmacies, particularly during peak allergy seasons. These stock-outs, while not indicative of a systemic supply failure, can disrupt treatment continuity for patients with allergic rhinitis and chronic urticaria.

This guide summarizes the current supply landscape, provides evidence-based guidance on therapeutic alternatives, and offers practical tools for managing patient concerns.

Understanding the Supply Landscape

Cetirizine occupies a unique position in the pharmacy marketplace. Originally FDA-approved as a prescription medication in 1995, it transitioned to over-the-counter status in 2007. Today, the vast majority of Cetirizine is sold OTC, manufactured by numerous generic producers in addition to the Johnson & Johnson brand (Zyrtec).

This broad manufacturer base generally insulates Cetirizine from the single-source vulnerabilities that drive shortages of many prescription medications. However, several factors contribute to periodic retail unavailability:

• Seasonal demand elasticity: Allergy medication purchases can increase 200-300% during peak pollen seasons, overwhelming retail inventory systems calibrated to average demand
• Retail inventory optimization: Modern just-in-time inventory management minimizes overstock but increases vulnerability to demand surges
• Store-brand preference: Generic and store-brand Cetirizine products, which offer significant cost advantages, experience disproportionate sell-through during high-demand periods
• Supply chain residual fragility: Post-pandemic supply chain normalization continues, with sporadic disruptions in active pharmaceutical ingredient (API) sourcing and distribution

Clinical Implications for Patient Management

Allergic Rhinitis

For patients using Cetirizine for seasonal or perennial allergic rhinitis, a temporary interruption in therapy is unlikely to cause significant harm but may lead to symptom breakthrough. Second-generation antihistamines do not require loading periods, so patients can resume full efficacy within 1-2 hours of taking any equivalent agent.

Per the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) guidelines, second-generation antihistamines are recommended as first-line pharmacotherapy for allergic rhinitis. Cetirizine, Loratadine, and Fexofenadine are considered therapeutically interchangeable for this indication.

Chronic Urticaria

For patients with chronic idiopathic urticaria (CIU), treatment continuity is more critical. The AAAAI/ACAAI guidelines recommend second-generation antihistamines as first-line therapy, with dose escalation up to 4x the standard dose before adding second-line agents. Patients on higher-dose regimens may face greater difficulty sourcing adequate quantities during stock-outs.

Clinicians should proactively discuss contingency plans with CIU patients, including:

• Identifying alternative pharmacies or online sources
• Pre-authorizing a therapeutic switch to Levocetirizine or another second-generation antihistamine
• Ensuring patients understand that Levocetirizine 5 mg provides comparable H1 blockade to Cetirizine 10 mg

Therapeutic Alternatives: Evidence-Based Substitution

When Cetirizine is unavailable, the following substitutions are supported by clinical evidence:

Levocetirizine (Xyzal) — Closest Pharmacologic Match

• Active R-enantiomer of Cetirizine
• Standard dose: 5 mg once daily (equivalent to Cetirizine 10 mg)
• Available OTC
• Same side effect profile; may have marginally less somnolence at equipotent doses
• First-line recommendation for CIU per AAAAI/ACAAI guidelines

Loratadine (Claritin)

• Standard dose: 10 mg once daily
• Less sedating than Cetirizine; may be preferred in patients reporting somnolence
• Slightly slower onset of action (1-3 hours vs. <1 hour for Cetirizine)
• Widely available OTC; extensive generic availability
• May be less effective than Cetirizine for urticaria in some patients

Fexofenadine (Allegra)

• Standard dose: 180 mg once daily or 60 mg twice daily
• Least sedating second-generation antihistamine
• Clinically important interaction with fruit juices (apple, orange, grapefruit) — reduced absorption via OATP inhibition
• Ideal for patients who cannot tolerate any sedation
• Available OTC

Desloratadine (Clarinex)

• Standard dose: 5 mg once daily
• Prescription only
• Active metabolite of Loratadine with potentially improved efficacy in some patients
• Non-sedating profile

Prescription-Only Cetirizine Formulations

Providers should be aware of the following prescription-only Cetirizine products, which have separate supply chains from OTC formulations:

• Quzyttir (Cetirizine injection): FDA-approved for acute urticaria in adults and children ≥6 months. Hospital/clinic use only.
• Zerviate (Cetirizine ophthalmic solution 0.24%): FDA-approved for allergic conjunctivitis. Separate supply chain from oral formulations.

If patients require these prescription formulations and encounter availability issues, consider contacting the manufacturers directly or exploring specialty pharmacy options.

Tools for Managing Patient Access

Several resources can help providers and their staff assist patients in locating Cetirizine:

• MedFinder for Providers: Real-time pharmacy inventory tracking that clinicians can use to direct patients to pharmacies with confirmed stock
• FDA Drug Shortage Database: Monitor accessdata.fda.gov for any changes in Cetirizine's shortage status
• Pharmacy transfer: Advise patients that OTC Cetirizine does not require a prescription transfer — they can simply purchase it at any location that has stock

Patient Communication Recommendations

When patients report difficulty finding Cetirizine, consider the following talking points:

1. Reassure: This is a localized stock-out, not a nationwide shortage. The medication is still being manufactured by multiple companies.
2. Redirect: Suggest checking other retailers, purchasing online, or using MedFinder to locate nearby availability.
3. Substitute if needed: Offer a specific alternative recommendation with dosing guidance so the patient can act immediately.
4. Educate on generics: Remind patients that all generic Cetirizine products are bioequivalent to Zyrtec and can be used interchangeably.
5. Plan ahead: Encourage patients to maintain a 60-90 day supply of their antihistamine, especially if they use it year-round.

Additional Resources

• How to help your patients find Cetirizine in stock: A provider's guide
• Cetirizine shortage update: What patients need to know (shareable with patients)
• Alternatives to Cetirizine (patient-facing resource)
• How to help patients save money on Cetirizine